Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936635 · ClinicalTrials.gov registry record · Phase 3
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
NCT02936635 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 280 participants.
The verdict
NCT02936635, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).
Interventions
- DRUG tirasemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2018-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02936635
The ClinicalTrials.gov registry entry for NCT02936635 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tirasemtiv is the first listed.
NCT02936635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02936635 about?
NCT02936635 is a clinical study titled "A Study for Patients Who Completed VITALITY-ALS (CY 4031)". The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).
What is the current status of trial NCT02936635?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2016-10-17. Estimated completion is 2018-10-26.
What interventions are being tested in trial NCT02936635?
The interventions under investigation include: tirasemtiv (DRUG).
Who is sponsoring clinical trial NCT02936635?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.